journal article·2021-04-15Open access

Transdermal System Based on Solid Cilostazol Nanoparticles Attenuates Ischemia/Reperfusion-Induced Brain Injury in Mice

Hiroko Otake, Mizuki Yamaguchi, Fumihiko Ogata, Saori Deguchi, Naoki Yamamoto, Hiroshi Sasaki, Naohito Kawasaki, Noriaki Nagai

Nanomaterials· Volume 11· Issue 4

Abstract

Cilostazol (CIL) exerted a protective effect by promoting blood–brain barrier integrity as well as improving the status of neurological dysfunctions following cerebral ischemia/reperfusion (I/R) injury. We attempted to design a 0.5% CIL carbopol gel using solid nanoparticles (CIL-Ngel), and then investigated the relationships between energy-dependent endocytosis and the skin penetration of CIL-Ngel in this study. In addition, we evaluated whether the CIL-Ngel attenuated I/R-induced brain injury in a middle cerebral artery occlusion (MCAO)/reperfusion model mouse. The particle size of CIL was decreased using a bead mill, and the CIL particles (14.9 × 1014 particles/0.3 g) in the CIL-Ngel were approximately 50–180 nm. The release of CIL in the CIL-Ngel was higher than that in gel containing CIL powder (CIL-Mgel), and the CIL particles were released from the CIL-Ngel as nanoparticles. In addition, the percutaneous absorption of CIL from the CIL-Ngel was higher in comparison with that from CIL-Mgel, and clathrin-dependent endocytosis and caveolae-dependent endocytosis were related to the enhanced skin penetration of CIL-NPs. In the traditional (oral administration of CIL powder, 3 mg/kg) and transdermal administration (CIL-Ngel, 0.3 g) for 3 days (once a day), the area under the plasma CIL concentration–time curves (AUC) was similar, although the CIL supplied to the blood by the CIL-Ngel was more sustained than that via oral administration of CIL powder. Furthermore, the CIL-Ngel attenuated the ischemic stroke. In conclusion, we designed a gel using solid CIL-NPs, and we showed that the sustained release of CIL by CIL-Ngel provided an effective treatment for ischemic stroke in MCAO/reperfusion model mice. These findings induce the possibilities of developing novel applications of CIL solid nanoparticles.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Neuroinflammation and Neurodegeneration Mechanisms · Pain Mechanisms and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka, Osaka 577-8502, Japan

Department of Ophthalmology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan

References (30)

Show source-provided references
1. Real-world outcomes of acute ischemic stroke treatment with intravenous recombinant tissue plasminogen activator10.1016/j.jstrokecerebrovasdis.2017.06.010 ↗
2. Reperfusion injury following cerebral ischemia: Pathophysiology, MR imaging, and potential therapies10.1007/s00234-006-0183-z ↗
3. Ischemia/reperfusion injury: Effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition10.1016/j.bcp.2013.12.013 ↗
4. Protein aggregation and proteasome dysfunction after brain ischemia10.1161/STROKEAHA.107.487108 ↗
5. Oxidative stress in neurodegenerative diseases
6. Ischemia-reperfusion injury in stroke10.1159/000353125 ↗
7. Revisiting cerebral postischemic reperfusion injury: New insights in understanding reperfusion failure, hemorrhage, and edema10.1111/ijs.12434 ↗
8. Role of inflammation and its mediators in acute ischemic stroke10.1007/s12265-013-9508-6 ↗
9. Cilostazol for preventation of secondary stroke (CSPS 2): An aspirin-controlled, double-blind, randomized non-inferiority trial10.1016/S1474-4422(10)70198-8 ↗
10. Cilostazol inhibits the redistribution of the actin cytoskeleton and junctional proteins on the blood–brain barrier under hypoxia/reoxygenation10.1016/j.phrs.2006.10.010 ↗
11. Cilostazol strengthens barrier integrity in brain endothelial cells10.1007/s10571-012-9896-1 ↗
12. Beneficial effect of cilostazol-mediated neuronal repair following trimethyltininduced neuronal loss in the dentate gyrus10.1002/jnr.23472 ↗
13. Intravenous administration of cilostazol nanoparticles ameliorates acute ischemic stroke in a cerebral ischemia/reperfusion-induced injury model10.3390/ijms161226166 ↗
14. An oral formulation of cilostazol nanoparticles enhances intestinal drug absorption in rats
15. Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers10.1016/j.jconrel.2013.10.007 ↗
16. Device-assisted transdermal drug delivery10.1016/j.addr.2017.08.009 ↗
17. Nanotechnology and the transdermal route: A state of the art review and critical appraisal10.1016/j.jconrel.2009.10.016 ↗
18. Palmer, B.C., and DeLouise, L.A. (2016). Nanoparticle-enabled transdermal drug delivery systems for enhanced dose control and tissue targeting. Molecules, 21.10.3390/molecules21121719 ↗
19. Nagai, N., Ogata, F., Ishii, M., Fukuoka, Y., Otake, H., Nakazawa, Y., and Kawasaki, N. (2018). Involvement of endocytosis in the transdermal penetration mechanism of ketoprofen nanoparticles. Int. J. Mol. Sci., 19.10.3390/ijms19072138 ↗
20. Nagai, N., Ogata, F., Yamaguchi, M., Fukuoka, Y., Otake, H., Nakazawa, Y., and Kawasaki, N. (2019). Combination with l-menthol enhances transdermal penetration of indomethacin solid nanoparticles. Int. J. Mol. Sci., 20.10.3390/ijms20153644 ↗
21. Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment10.2147/IJN.S173216 ↗
22. Nagai, N., Deguchi, S., Otake, H., Hiramatsu, N., and Yamamoto, N. (2017). Therapeutic effect of cilostazol ophthalmic nanodispersions on retinal dysfunction in streptozotocin-induced diabetic rats. Int. J. Mol. Sci., 18.10.3390/ijms18091971 ↗
23. Cold atmospheric plasma induces ATP-dependent endocytosis of nanoparticles and synergistic U373MG cancer cell death10.1038/s41598-018-23262-0 ↗
24. The role of endocytosis on the uptake kinetics of luciferin-conjugated cell-penetrating peptides10.1016/j.bbamem.2011.11.020 ↗
25. The effect of dynasore, a blocker of dynamin-dependent endocytosis, on spontaneous quantal and non-quantal release of acetylcholine in murine neuromuscular junctions10.1134/S0012496614060052 ↗
26. Fluid phase endocytosis contributes to transfection of DNA by PEI-2510.1038/mt.2009.121 ↗
27. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion10.1097/00004647-199607000-00010 ↗
28. Neuroprotection by CLZ, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion10.1016/j.brainres.2006.01.088 ↗
29. Novel situations of endothelial injury in stroke–mechanisms of stroke and strategy of drug development: Protective effects of antiplatelet agents against stroke10.1254/jphs.10R26FM ↗
30. Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage10.1016/j.neulet.2009.01.039 ↗